<code id='130F75441D'></code><style id='130F75441D'></style>
    • <acronym id='130F75441D'></acronym>
      <center id='130F75441D'><center id='130F75441D'><tfoot id='130F75441D'></tfoot></center><abbr id='130F75441D'><dir id='130F75441D'><tfoot id='130F75441D'></tfoot><noframes id='130F75441D'>

    • <optgroup id='130F75441D'><strike id='130F75441D'><sup id='130F75441D'></sup></strike><code id='130F75441D'></code></optgroup>
        1. <b id='130F75441D'><label id='130F75441D'><select id='130F75441D'><dt id='130F75441D'><span id='130F75441D'></span></dt></select></label></b><u id='130F75441D'></u>
          <i id='130F75441D'><strike id='130F75441D'><tt id='130F75441D'><pre id='130F75441D'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:explore    Page View:17983
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In